Werewolf Therapeutics (HOWL) has shared an update.
Werewolf Therapeutics, Inc. announced promising early results from a Phase 1 clinical trial for WTX-330, a novel cancer treatment targeting advanced solid tumors and non-Hodgkin lymphoma. The study showed that WTX-330 delivered significantly higher systemic concentrations of its active ingredient compared to previous treatments, with one patient achieving a partial response and others stable disease. Despite mild to moderate side effects, no severe adverse events were reported, and the trial has expanded to include more patients, especially those resistant to current immunotherapies.
For detailed information about HOWL stock, go to TipRanks’ Stock Analysis page.
